Lilly's Retatrutide Posts 28% Weight Loss in Phase Three

May 21. Eli Lilly released Phase Three data for retatrutide, its next-generation weight loss injectable. Nearly half of patients on the high dose lost 28% of body weight over 48 weeks. That's bariatric surgery territory, delivered subcutaneously.

Shares moved up in premarket trading. The drug isn't approved yet, but the data puts Lilly ahead of Novo Nordisk's semaglutide (Wegovy) and tirzepatide (Mounjaro's competitor). Retatrutide works on three hormone pathways instead of two. The result: faster, deeper weight loss with fewer plateau complaints.

The fashion read

GLP-1s reshaped sample sizing twice already. First wave: brands adjusted for patients on Wegovy. Second: tirzepatide patients went smaller again. Retatrutide's 28% average suggests another round of size-chart revisions incoming. That's not speculation. It's logistics.

Quiet-luxury houses already leaned into tailoring that accommodates fluctuation (The Row's elastic waistbands, Lemaire's dropped shoulders). Retatrutide makes that design philosophy load-bearing. A customer who drops three sizes in 48 weeks isn't buying fewer pieces. She's buying different pieces, more frequently, in categories that forgive.

What moves

Accessories and outerwear hold stable across weight flux. Bags, shoes, coats, scarves. Tailored trousers and fitted knits rotate faster. Resale platforms already see GLP-1 churn in their data (Vestiaire Collective flagged it in a Q4 call). Retatrutide accelerates that.

Lilly hasn't priced the drug yet. Wegovy runs $1,300/month in the U.S. without insurance. If retatrutide lands at $1,500+ and moves to market in 2027, the addressable customer base contracts to the same demo already shopping Loewe and Bottega. Not mass. Not yet.

The trial enrolled 1,100 patients. FDA approval timeline is 18–24 months if the data holds. By then, three drugs will be competing in the same weight-loss lane, and fashion's sample-size churn will be permanent architecture, not a moment.